Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLN 
Silence Therapeutics PLC (SLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: SLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $33.94
1 Year Target Price $33.94
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 134.5% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 226.72M USD | Price to earnings Ratio - | 1Y Target Price 33.94 |
Price to earnings Ratio - | 1Y Target Price 33.94 | ||
Volume (30-day avg) 7 | Beta 1.38 | 52 Weeks Range 1.97 - 20.48 | Updated Date 09/16/2025 |
52 Weeks Range 1.97 - 20.48 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -291.24% | Operating Margin (TTM) -9048.21% |
Management Effectiveness
Return on Assets (TTM) -22.25% | Return on Equity (TTM) -66.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 90248956 | Price to Sales(TTM) 8.34 |
Enterprise Value 90248956 | Price to Sales(TTM) 8.34 | ||
Enterprise Value to Revenue 3.32 | Enterprise Value to EBITDA -5.78 | Shares Outstanding 47233900 | Shares Floating 74747724 |
Shares Outstanding 47233900 | Shares Floating 74747724 | ||
Percent Insiders 24.38 | Percent Institutions 44.31 |
Upturn AI SWOT
Silence Therapeutics PLC
Company Overview
History and Background
Silence Therapeutics, founded in 1994, pioneered siRNA therapeutics. Initially focused on gene silencing technology, it has evolved into a clinical-stage biotechnology company developing next-generation siRNA therapeutics for various diseases.
Core Business Areas
- siRNA Therapeutics Development: Develops and commercializes siRNA-based drugs targeting specific genes to treat diseases.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure includes research and development, clinical operations, and commercialization functions.
Top Products and Market Share
Key Offerings
- SLN360: A siRNA therapeutic targeting lipoprotein(a) (Lp(a)) for cardiovascular disease. Currently in clinical trials. Competitors include Novartis and Amgen in the Lp(a) reducing space. Market share data unavailable as product is not yet commercialized. Focus is reducing Lp(a) levels which in turn can reduce cardiovascular risks and incidents.
- SLN124: A siRNA therapeutic targeting TMPRSS6 for iron overload disorders. Currently in clinical trials. Competitors are companies developing treatments for anemia and iron overload, such as Protagonist Therapeutics and Disc Medicine. Market share data unavailable as product is not yet commercialized. Focus is hepcidin modulation to improve erythropoiesis.
Market Dynamics
Industry Overview
The RNAi therapeutics market is growing rapidly, driven by technological advancements and increasing investment in drug development. The market is becoming increasingly competitive with both large pharmaceutical companies and smaller biotech firms.
Positioning
Silence Therapeutics is a specialized biotechnology company with expertise in siRNA technology. Its competitive advantage lies in its proprietary mRNAiGOLD platform and its focus on developing highly targeted therapeutics.
Total Addressable Market (TAM)
The total addressable market for siRNA therapeutics is estimated to reach billions of dollars in the coming years. Silence Therapeutics aims to capture a significant share of this market by targeting specific disease areas with high unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary mRNAiGOLD platform
- Strong intellectual property portfolio
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- Reliance on partnerships for commercialization
Opportunities
- Expanding into new therapeutic areas
- Securing partnerships with larger pharmaceutical companies
- Advancing pipeline candidates through clinical development
- Growing demand for RNAi therapeutics
Threats
- Competition from other RNAi therapeutics companies
- Regulatory hurdles
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- ALNY
- VIR
- IONS
Competitive Landscape
Silence Therapeutics faces competition from established RNAi therapeutics companies. Its competitive advantage lies in its mRNAiGOLD platform, but its smaller size and limited resources compared to larger companies present challenges.
Growth Trajectory and Initiatives
Historical Growth: Silence Therapeutics' historical growth has been driven by its advancements in siRNA technology and progression of its clinical pipeline.
Future Projections: Future growth is projected to be driven by successful clinical trial outcomes, regulatory approvals, and commercialization of its siRNA therapeutics.
Recent Initiatives: Recent initiatives include advancing SLN360 and SLN124 through clinical trials, expanding its pipeline through internal research and development, and seeking strategic partnerships.
Summary
Silence Therapeutics is a biotech company with a promising siRNA platform. Clinical trial successes are vital for future growth. Competition in the RNAi therapeutics market poses challenges. Strategic partnerships are crucial for commercialization and expanding its market reach. Financial stability is essential for continued advancement.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Silence Therapeutics PLC website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market data and projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Silence Therapeutics PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-08 | President, CEO & Executive Director Mr. Craig A. Tooman M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | |
Full time employees 116 | |||
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.